Powerful Drug for Advanced Cancers May Need Less Frequent Dosing

WEDNESDAY, Jan. 4, 2017 -- Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid...
Source: Drugs.com - Daily MedNews - Category: Journals (General) Source Type: news

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
CONCLUSION: Our findings show that PLK4 inhibitors were effective against Ewing's sarcoma cells in vitro and thus provide a rationale for their evaluation in vivo. PMID: 32770382 [PubMed - indexed for MEDLINE]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
(Impact Journals LLC) The cover for issue 40 of Oncotarget features Figure 5, " miR-210 silences the proapoptosis member CASP8AP2, " by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them. For the first time, fusion genes have been selectively and efficiently removed using CRISPR. These genes are attracting a great deal of interest from the research community because they are unique to the tumor cell and are therefore excellent targets for the development of future drugs that only attack the tumor and are harmless for healthy cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c12769
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
We report a successful case of a customized prosthesis using a 3D ‐printed titanium alloy to repair and reconstruct bone defects in a patient with sternal osteosarcoma who underwent radical resection of the whole sternum. After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three ‐dimensional (3D)‐printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stability and robustness of the prosthesis. Here, we report a successful case of a customi...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma. Mol Med Rep. 2020 Nov;22(5):3911-3921 Authors: Meng CY, Zhao ZQ, Bai R, Zhao W, Wang YX, Sun L, Sun C, Feng W, Guo SB Abstract Osteosarcoma (OS) is a primary malignant tumor of bone tissue. Effective chemotherapy may improve the survival of patients with OS. MicroRNAs (miRs) serve significant roles in the regulatory function of tumorigenesis and chemosensitivity of different types of cancer. miR‑22 has been revealed to inhibit the proliferation and migration of OS cells, as well as increasing their sensitivi...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Recently, the rapid development of biomaterials has induced great interest in the precisely targeted treatment of bone-related diseases, including bone cancers, infections, and inflammation. Realizing noninvasive therapeutic effects, as well as improving bone tissue regeneration, is essential for the success of bone‑related disease therapies. In recent years, researchers have focused on the development of stimuli-responsive strategies to treat bone-related diseases and to realize bone regeneration. Among the various external stimuli for targeted therapy, near infrared (NIR) light has attracted considerable interests due ...
Source: Theranostics - Category: Molecular Biology Authors: Tags: Review Source Type: research
(Medical University of South Carolina) Innova Therapeutics Inc. recently announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation for IVT-8086 for the treatment of osteosarcoma. MUSC Hollings Cancer Center researcher Nancy Klauber-DeMore, M.D., was instrumental in the development of the research that led to the therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Osteosarcoma (OS) is one of the most primary malignant bone tumors, mainly attracting children and young adults. The microRNAs are mentioned to play vital roles in many cancers, including OS. The purpose of th...
Source: Journal of Orthopaedic Surgery and Research - Category: Orthopaedics Authors: Tags: Research article Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | General Medicine | Reclast | Study | Zometa